Загрузка...
Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
PURPOSE: There has been no extensive study to compare the efficacy between rituximab originator (Mabthera®) and its biosimilar (Truxima®) for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Here, we investigated the clinical effects of rituximab on poor outcomes of MPA and...
Сохранить в:
| Опубликовано в: : | Yonsei Med J |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Yonsei University College of Medicine
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7393299/ https://ncbi.nlm.nih.gov/pubmed/32734735 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3349/ymj.2020.61.8.712 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|